Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. has increased its investment in InStatin, which is developing an innovative inhaled statin solution for chronic lung conditions like asthma and COPD. The company anticipates substantial growth in the asthma treatment market, expecting to reach USD $30.1 billion by 2030, indicating a promising future for its investment. Therma Bright looks forward to the potential positive outcomes from InStatin’s upcoming clinical trials.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
